Med Ad Hall of Fame to induct Lerner, Girgenti and Rubin

Share this article:
A 1960s ad for Librium
A 1960s ad for Librium
The Medical Advertising Hall of Fame named former Roche chief Irwin Lerner and medical advertising men Steven Girgenti and Mel Rubin as its 2010 inductees.

Having started his career with Organon as a copywriter and worked as a sales promotion manager with Geigy Pharmaceuticals, Lerner joined Roche in 1962 as advertising product manager for Librium and was named director of advertising ahead of the launch of Valium. He went on to spend 32 years with the company – 12 of them as CEO – during which he developed successful campaigns positioning Librium for anxiety and Valium for psychic tension, introduced a private hospital TV network and forged the lucrative Roche/GSK co-promotion deals for Zantac and Ceftin.

Girgenti, most recently of Ogilvy Healthworld, got his start with Squibb, Carter Wallace and Endo DuPont, where he was instrumental in the development and launch of Percocet. He moved on to superagency William Douglas McAdams before co-founding Bologna International and then Girgenti, Hughes, Butler & McDowell, along the way creating a logarithm for Theo Dur that helped boost sales from $12 million to $100 million in under three years. He took Girgenti, Hughes, Butler & McDowell public in 1997.

Rubin, a copywriter, founded the Shaller Rubin Company in 1950, an agency with clients including Schering, Geigy, Ciba, Pfizer, Marion Merrel Dow and Norwich Eaton. He was an early advocate of DTC TV advertising and his shop Rubin, Reid, Noto and Ehrenthal was the launch agency for Marion Merrell Dow's Nicorette gum TV campaign, the first-ever branded TV campaign for a prescription drug.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.